PEŘINA, Vojtěch, Zdeněk DANĚK and Oliver BULIK. Osteonecrosis of the jaw in FN Brno - years 2004 - 2012 analysis. In Sborník abstrakt, 10. česko-slovensko-polské trilaterální sympozium orální a maxilofaciální chirurgie a 2. národní kongres Společnosti maxilofaciální chirurgie, 07.-09.11.2013, Velké Karlovice. 2013. ISBN 978-80-87562-11-6.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Osteonecrosis of the jaw in FN Brno - years 2004 - 2012 analysis.
Name in Czech Osteonekrózy čelisti ve FN Brno - analýza let 2004 - 2012.
Authors PEŘINA, Vojtěch, Zdeněk DANĚK and Oliver BULIK.
Edition Sborník abstrakt, 10. česko-slovensko-polské trilaterální sympozium orální a maxilofaciální chirurgie a 2. národní kongres Společnosti maxilofaciální chirurgie, 07.-09.11.2013, Velké Karlovice, 2013.
Other information
Type of outcome Conference abstract
Confidentiality degree is not subject to a state or trade secret
ISBN 978-80-87562-11-6
Changed by Changed by: doc. MUDr. et MUDr. Vojtěch Peřina, Ph.D., učo 21084. Changed: 13/7/2014 13:35.
Abstract
Bisphosphonates (BP) are widely used in the management of metastatic bone disease including multiple myeloma (MM) and in the treatment of osteoporosis or Paget's disease. The association between BP treatment and osteonecrosis of the jaw is known since 2003. During years 2004 - 2012 we have diagnosed 93 patients with BP-associated osteonecrosis of the jaw (BPOJ). The most common main diagnoses were MM and solid cancers bone metastases. While number of patient with MM and BPOJ stays relatively stable (aprox. 5 patients per year) number of patients with bone metastases rise each year (from 0 in the year 2004 to 17 in 2012). One reason is undoubtedly wider use of BP for bone metastases treatment nowadays. But we noticed worse patient's education and preventive measures among patients with solid cancers. This is probably due to higher centralization of hematooncological care and closer cooperation between hematooncologists and OMF surgeons in our hospital. The general oncological and supportive care is more fragmented and the risk of BPOJ is not well known. In the future better patient's education and wider interdisciplinary cooperation will be necessary. Early diagnosis (even before clinical manifestation of BPOJ), would be advantageous. But then most suitable modality is still open question.
Links
GAP102/11/0318, research and development projectName: Analýza metabolizmu a lokalizace změn kostní tkáně čelisti pomocí MR zobrazovacích technik
Investor: Czech Science Foundation
PrintDisplayed: 31/7/2024 13:26